WILMINGTON, Del. (AP) - A Delaware pharmaceutical company’s lawsuit alleging that a high-ranking scientist stole company secrets and shared them with a Silicon Valley startup went to trial this week.
The News Journal reports that during Tuesday’s opening statement, Incyte Corp. attorney Steve Wood accused Flexus Biosciences of employing “a spy and a sellout” to steal information about blood tests and how a potential cancer-fighting drug metabolized.
In 2014, Jordan Fridman left Incyte to become the head of cancer research at Flexus. The lawsuit accuses Flexus of using Incyte’s confidential information to develop an immunotherapy cancer drug and sell themselves to Bristol-Myers Squibb for $1.25 billion.
Flexus attorney James Hurst asserted Tuesday that the information in contention was relatively simple to independently discover and just “specks in an ocean of research and experimentation.”
Please read our comment policy before commenting.